Drug Profile

Seasonal influenza virus vaccine high dose - Sanofi Pasteur

Alternative Names: Fluzone HD; Fluzone^® High Dose IM; Fluzone^® High-Dose influenza vaccine; Seasonal influenza virus vaccine - sanofi

Latest Information Update: 27 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi pasteur
Developer Peter MacCallum Cancer Centre; Sanofi; Sanofi K.K.
Class Influenza virus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Influenza virus infections

Most Recent Events

27 May 2026 Sanofi anticipates the regulatory approval decision from the US and the EU in 2027
23 Apr 2026 Preregistration for Influenza virus infections in European Union (IM)
23 Apr 2026 Sanofi files sBLA to US FDA for Influenza virus infections in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com